Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 127

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 127
---
 firm for purposes of soliciting proxies in connection with the Arrangement; or |

| (ii) | not announce an intention, enter into any formal or informal agreement, or otherwise make a commitment to do 
 any of the things prohibited by any of the foregoing subsections.                                            |

Notwithstanding the foregoing, the Company is entitled, but is under no obligation, to sell, transfer, license, assign or otherwise divest any or all of the Company’s and its Subsidiary’s rights, Intellectual Property, and other assets related to (i) the RP-3467program, a Pol qATPase Inhibitor, (ii) the RP-1664program, a polo-like kinase 4 (PLK4) inhibitor, (iii) the RP-3500(camonsertib) program, an ATR inhibitor, and/or (iv) an undisclosed preclinical program, in one or more transactions (each a “ Permitted Disposition” and collectively, the “ Permitted Dispositions”) prior to the Effective Date; provided, however, that if any such Permitted Disposition results in the imposition of ongoing obligations (including indemnification obligations or potential post-closing claims for breach of contract) or liabilities on the Company or the Subsidiary, the terms of the Permitted Disposition relating to such obligations or liabilities shall be acceptable to the Purchaser, acting reasonably, it being acknowledged that any such Permitted Disposition that is without recourse to the Company (such as an as-istransaction or one where post-closing liability is limited solely to escrowed sale proceeds (together with a sole and exclusive remedy clause confirming the same) or one where recourses of the applicable purchaser are limited solely to rights and recourses under a representations and warranties insurance policy (together with a sole and exclusive remedy clause confirming the same), coupled with a waiver of subrogation rights in favor of 76

the Company and its Subsidiary) and does not impose any obligations or liabilities on the Company or its Subsidiary beyond those obligations and liabilities outstanding as at the date of the
Agreement, shall be deemed acceptable to the Purchaser.

The Company agreed that it shall use its commercially reasonable efforts to cause
the current material insurance (or re-insurance) policies maintained by the Company or the Subsidiary not to be cancelled or terminated or any of the coverage thereunder to lapse, unless at the time of such
termination, cancellation or lapse, replacement policies under